Lumateperone tosylate

甲苯磺酸卢美哌隆

Report date: 2025/08/27 20:01:50
NME

Base Information

Drug NameLumateperone tosylate
Drug Alias NameLumateperonum卢美哌隆Lumateperona鲁玛哌隆Lumateperone +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 2a (5-HT2a) receptor antagonistsDopamine D2 receptor antagonists
TargetsSerotonin 2a (5-HT2a) receptorDopamine D2 receptor
Therapy Area/IndicationsSchizoaffective disorderSchizophreniaPsychotic Disorders +[10] 
Global Approved IndicationsSchizophrenia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/12/20
Country/TerritoryCzechiaBulgariaUnited States +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesIntra-Cellular Therapies IncThe University Of ChicagoLouisiana State University Health Sciences Center Shreveport +[7] 
Inactive CompaniesNew York State Psychiatric Institute
Active IndicationsSchizoaffective disorderSchizophreniaPsychotic Disorders +[9] 
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN05A
Related LinksWikipediaDrugBankKEGG